Your browser doesn't support javascript.
loading
NPS-EQA PART II: Four years' experience in external quality assessment program in Italy for classical and new psychoactive substances analysis in hair.
Rotolo, Maria Concetta; Graziano, Silvia; Varì, Maria Rosaria; Minutillo, Adele; Di Giorgi, Alessandro; Aquilina, Valeria; Pichini, Simona; Marchei, Emilia.
Afiliación
  • Rotolo MC; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
  • Graziano S; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
  • Varì MR; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
  • Minutillo A; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
  • Di Giorgi A; Department of Biomedical Science and Public Health, University Politecnica delle Marche, Ancona, Italy.
  • Aquilina V; Investigation, Crime and International Security, Università degli Studi Internazionali di Roma - UNINT, Rome, Italy.
  • Pichini S; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy. Electronic address: simona.pichini@iss.it.
  • Marchei E; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
J Pharm Biomed Anal ; 243: 116100, 2024 Jun 15.
Article en En | MEDLINE | ID: mdl-38513500
ABSTRACT
In 2019, the Italian National Institute of Health established an external quality assessment (EQA) program to evaluate the performance of laboratories of collaborative centres participating in the National Early Warning System in hair testing for classical and new psychoactive substances (NPS). The results obtained in the four rounds (2019-2023) and the evolution in hair testing performance for classic drugs of abuse and new psychoactive substances are presented. A total of 11 hair specimens, including 3 blank samples, were prepared by adding different classes of classical and NPS at known concentrations to pre-screened drug-free hair. False negative and false positive results were calculated for the qualitative data evaluation. The quantitative evaluation included the imprecision (as % coefficient of variation, CV%) and the accuracy (as % error, ERR%) of the results with respect to a mean value obtained by reference laboratories and Z-score values were assessed. Over the years, an improvement in false negative results (from 52.4% in the first year to 34.3% in the last one) and false positive results (from 55.0% in the first year to 30.8.% in the last one) was observed. In the first round, the mean ERR% ranged from 6.2% to 112.8% due to NPS determination. However, in the subsequent three rounds, the mean ERR% ranged from 10.4% to 22.4%, The mean CV% in the four rounds was approximately 41.5% (ranging from 44.3% to 53.3%). Between 12.0% and 56.6% of the reported results in all rounds should be considered satisfactory. EQA programs help laboratories to identify and correct problems within their processes by highlighting errors and variations. This ensures that the results produced are accurate and reproducible.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos del Sistema Nervioso Central / Cabello País/Región como asunto: Europa Idioma: En Revista: J Pharm Biomed Anal Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos del Sistema Nervioso Central / Cabello País/Región como asunto: Europa Idioma: En Revista: J Pharm Biomed Anal Año: 2024 Tipo del documento: Article País de afiliación: Italia